Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT)

Anthony H. Kashou, Peter A. Noseworthy

Research output: Contribution to journalArticle

Abstract

Introduction: Paroxysmal supraventricular tachycardia (SVT) can be very bothersome and may potentially lead to considerable health-care utilization. Non-parenteral medication is currently unavailable for the rapid termination of paroxysmal SVT. However, an intranasal spray formulation of etripamil, a short-acting calcium-channel blocker, is under investigation as a convenient, safe, and rapidly efficacious means to terminate paroxysmal SVT. Areas covered: This review summarizes the clinical rationale, potential benefit, and clinical trials safety and efficacy data for the use of etripamil nasal spray to terminate paroxysmal SVT. Expert opinion: Based on the efficacy and tolerability demonstrated in phase 1 and 2 clinical trials, etripamil nasal spray is a potential convenient, safe, and effective means for patients to terminate paroxysmal SVT. It has the potential to improve quality of life, reduce health-care burden, and alter the current management paradigm for many patients with SVT. Further ongoing evaluation in ambulatory patients will help to determine its real-life practicality, safety, and effectiveness.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalExpert Opinion on Investigational Drugs
Volume29
Issue number1
DOIs
StatePublished - Jan 2 2020

Keywords

  • Atrioventricular nodal reentrant tachycardia
  • atrioventricular reciprocating tachycardia
  • calcium-channel blocker
  • etripamil nasal spray
  • paroxysmal supraventricular tachycardia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT)'. Together they form a unique fingerprint.

  • Cite this